Clinical studies have become increasingly virtual because of COVID-19. How has this affected the way the FDA inspects clinical trials? Join Darshan Kulkarni as he talks with former FDA auditor Patrick Stone about his experience investigating sites and sponsors. Plus, we’ll discuss why virtual monitoring may be more cost-effective than other options.
How can you ensure readiness and compliance for FDA inspections? It is important for companies to investigate who the FDA targets, and how...
Companies must develop a plan to ensure that they are in compliance during inspections to ensure FDA readiness
Opening up lines of communication with the FDA can often be intimidating for companies, and the process does not seem straightforward...
